Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
2.

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B.

Cancer Immunol Immunother. 2018 Dec;67(12):1845-1851. doi: 10.1007/s00262-018-2244-7. Epub 2018 Sep 14.

PMID:
30218171
3.

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Simon B, Wiesinger M, März J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, Dörrie J, Uslu U.

Int J Mol Sci. 2018 Aug 11;19(8). pii: E2365. doi: 10.3390/ijms19082365.

4.

Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions.

Forschner A, Keim U, Hofmann M, Spänkuch I, Lomberg D, Weide B, Tampouri I, Eigentler T, Fink C, Garbe C, Haenssle HA.

Br J Dermatol. 2018 Aug;179(2):478-485. doi: 10.1111/bjd.16565. Epub 2018 Jun 7.

PMID:
29569229
5.

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN.

Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5.

6.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Leuk Lymphoma. 2018 Aug;59(8):1949-1958. doi: 10.1080/10428194.2017.1403022. Epub 2018 Jan 3.

PMID:
29295645
7.

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R; German Dermatooncology Group (DeCOG/ADO).

Cancer Med. 2018 Jan;7(1):95-104. doi: 10.1002/cam4.1267. Epub 2017 Dec 20.

8.

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.

Gaiser MR, Skorokhod A, Gransheier D, Weide B, Koch W, Schif B, Enk A, Garbe C, Bauer J.

PLoS One. 2017 Nov 27;12(11):e0188602. doi: 10.1371/journal.pone.0188602. eCollection 2017.

9.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

10.

Durch Pembrolizumab verursachte Hepatitis: Diagnose und Behandlung.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037_g. No abstract available.

PMID:
28872244
11.

Pembrolizumab-induced hepatitis: diagnosis and treatment.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037. No abstract available.

PMID:
28872228
12.

Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Eigentler TK, Keim U, Goebeler M, Fiedler E, Schuler G, Leiter U, Weide B, Grischke EM, Martus P, Garbe C.

J Invest Dermatol. 2017 Dec;137(12):2570-2577. doi: 10.1016/j.jid.2017.07.006. Epub 2017 Jul 21.

13.

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1977-1984. doi: 10.1007/s00432-017-2450-2. Epub 2017 Jun 14.

PMID:
28616701
14.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kähler KC, Gesierich A, Meissner M, von Bubnoff D, Göppner D, Schlaak M, Pföhler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C.

Eur J Cancer. 2017 Aug;81:36-44. doi: 10.1016/j.ejca.2017.05.014. Epub 2017 Jun 7.

PMID:
28600969
15.

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A.

Nat Commun. 2017 May 31;8:15440. doi: 10.1038/ncomms15440.

16.

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA, Wolchok JD, Blank CU, Garbe C, Pawelec G, Weide B.

Eur J Cancer. 2017 Mar;73:61-70. doi: 10.1016/j.ejca.2016.12.011. Epub 2017 Feb 4.

17.

Intralesional treatment of metastatic melanoma: a review of therapeutic options.

Weide B, Neri D, Elia G.

Cancer Immunol Immunother. 2017 May;66(5):647-656. doi: 10.1007/s00262-016-1952-0. Epub 2017 Jan 11. Review.

18.

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.

Weide B, Martens A, Wistuba-Hamprecht K, Zelba H, Maier L, Lipp HP, Klumpp BD, Soffel D, Eigentler TK, Garbe C.

Cancer Immunol Immunother. 2017 Apr;66(4):441-449. doi: 10.1007/s00262-016-1944-0. Epub 2016 Dec 22.

PMID:
28008452
19.

Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.

Wistuba-Hamprecht K, Martens A, Weide B, Teng KW, Zelba H, Guffart E, Chen J, Garbe C, Newell EW, Larbi A, Pawelec G.

J Immunol. 2017 Jan 15;198(2):927-936. doi: 10.4049/jimmunol.1600875. Epub 2016 Dec 16.

20.

Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.

Speigl L, Janssen N, Weide B, Pawelec G, Shipp C.

Br J Dermatol. 2017 Nov;177(5):1447-1449. doi: 10.1111/bjd.15194. Epub 2017 Jul 9. No abstract available.

PMID:
27870003
21.

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F.

Clin Cancer Res. 2016 Dec 1;22(23):5818-5828. Epub 2016 Jun 15. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1361.

22.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD.

Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16.

23.

High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.

Weide B, Schäfer T, Martens A, Kuzkina A, Uder L, Noor S, Garbe C, Harter PN, Mittelbronn M, Wischhusen J.

J Invest Dermatol. 2016 Dec;136(12):2444-2452. doi: 10.1016/j.jid.2016.07.016. Epub 2016 Oct 2.

24.

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B.

Eur J Cancer. 2016 Sep;64:116-26. doi: 10.1016/j.ejca.2016.06.001. Epub 2016 Jul 9.

25.

GSTP1 does not modify MC1R effects on melanoma risk.

Daley GM, Duffy DL, Pflugfelder A, Jagirdar K, Lee KJ, Yong XLH, Eigentler TK, Weide B, Smithers BM, Martin NG, Garbe C, Soyer HP, Sturm RA.

Exp Dermatol. 2017 Aug;26(8):730-733. doi: 10.1111/exd.13114. Epub 2017 Mar 23. No abstract available.

PMID:
27304781
26.

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.

Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, Pawelec G, Garbe C, Weide B.

Clin Cancer Res. 2016 Oct 1;22(19):4848-4858. Epub 2016 May 11.

27.

High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera.

Ritz D, Gloger A, Weide B, Garbe C, Neri D, Fugmann T.

Proteomics. 2016 May;16(10):1570-80. doi: 10.1002/pmic.201500445.

28.

Vemurafenib-induced granuloma annulare.

Lee SB, Weide B, Ugurel S, Mössner R, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2016 Mar;14(3):305-8. doi: 10.1111/ddg.12777. No abstract available.

PMID:
26972200
29.

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L.

J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.

30.

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Flores C, Chen L, Kwon BS, Borg C, Weide B, Aubin F, Dalle S, Kohrt H, Ayyoub M, Kroemer G, Marabelle A, Cavalcanti A, Eggermont A, Zitvogel L.

J Invest Dermatol. 2016 May;136(5):994-1001. doi: 10.1016/j.jid.2015.12.042. Epub 2016 Jan 29.

31.

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B.

Clin Cancer Res. 2016 Jun 15;22(12):2908-18. doi: 10.1158/1078-0432.CCR-15-2412. Epub 2016 Jan 19.

32.

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M.

Oncotarget. 2015 Dec 1;6(38):40836-49. doi: 10.18632/oncotarget.5696.

33.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

34.

Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanoma.

Wistuba-Hamprecht K, Di Benedetto S, Schilling B, Sucker A, Schadendorf D, Garbe C, Weide B, Pawelec G.

Int J Cancer. 2016 Feb 1;138(3):698-704. doi: 10.1002/ijc.29818. Epub 2015 Sep 18.

35.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA.

Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10. Erratum in: Science. 2015 Nov 13;350(6262):aad8366. Science. 2016 Apr 15;352(6283). pii: aaf8264. doi: 10.1126/science.aaf8264.

36.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

37.

The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma.

Zelba H, Weide B, Martens A, Bailur JK, Garbe C, Pawelec G.

Oncoimmunology. 2015 Jan 30;4(1):e955683. eCollection 2015 Jan.

38.

Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?

Tolk H, Satzger I, Mohr P, Zimmer L, Weide B, Schäd S, Gutzmer R.

Melanoma Res. 2015 Aug;25(4):362-6. doi: 10.1097/CMR.0000000000000169.

PMID:
26061438
39.

Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.

Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, Gebhardt C.

Int J Cancer. 2015 Dec 1;137(11):2607-17. doi: 10.1002/ijc.29619. Epub 2015 Jul 14.

40.

Increased CCL17 serum levels are associated with improved survival in advanced melanoma.

Weide B, Allgaier N, Hector A, Forschner A, Leiter U, Eigentler TK, Garbe C, Hartl D.

Cancer Immunol Immunother. 2015 Sep;64(9):1075-82. doi: 10.1007/s00262-015-1714-4. Epub 2015 May 20.

PMID:
25990074
41.

Immunologic correlates in the course of treatment with immunomodulating antibodies.

Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L.

Semin Oncol. 2015 Jun;42(3):448-58. doi: 10.1053/j.seminoncol.2015.02.016. Epub 2015 Feb 13. Review.

PMID:
25965363
42.

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5. doi: 10.1073/pnas.1417320112. Epub 2015 Apr 27.

43.

Melanoma brain metastasis is independent of lactate dehydrogenase A expression.

Sundstrøm T, Espedal H, Harter PN, Fasmer KE, Skaftnesmo KO, Horn S, Hodneland E, Mittelbronn M, Weide B, Beschorner R, Bender B, Rygh CB, Lund-Johansen M, Bjerkvig R, Thorsen F.

Neuro Oncol. 2015 Oct;17(10):1374-85. doi: 10.1093/neuonc/nov040. Epub 2015 Mar 19.

44.

Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival.

Leiter U, Eigentler TK, Häfner HM, Krimmel M, Uslu U, Keim U, Weide B, Breuninger H, Martus P, Garbe C.

Ann Surg Oncol. 2015 Nov;22(12):4073-80. doi: 10.1245/s10434-015-4439-x. Epub 2015 Feb 25.

PMID:
25712801
45.

Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial.

Pflugfelder A, Andonov E, Weide B, Dirschka T, Schempp C, Stockfleth E, Stratigos A, Krüger-Krasagakis S, Bauer J, Garbe C, Eigentler TK.

Br J Dermatol. 2015 Apr;172(4):926-32. doi: 10.1111/bjd.13342. Epub 2015 Feb 25.

PMID:
25124939
46.

Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.

Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C.

J Immunother. 2014 Sep;37(7):374-81. doi: 10.1097/CJI.0000000000000046.

PMID:
25075567
47.

Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment.

Winkler A, Plugfelder A, Weide B, Leiter U, Held L, Garbe C, Eigentler T.

Int J Dermatol. 2015 Apr;54(4):419-23. doi: 10.1111/ijd.12360. Epub 2014 Jul 29.

PMID:
25069527
48.

Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.

Weide B, Eigentler TK, Elia G, Neri D, Garbe C.

Cancer Immunol Immunother. 2014 Nov;63(11):1231-2. doi: 10.1007/s00262-014-1584-1. Epub 2014 Jul 24. No abstract available.

PMID:
25056818
49.

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.

Zelba H, Weide B, Martens A, Derhovanessian E, Bailur JK, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries J, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Aug 15;20(16):4390-9. doi: 10.1158/1078-0432.CCR-14-1015. Epub 2014 Jun 17.

50.

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C.

Cancer Immunol Res. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4.

Supplemental Content

Support Center